292 related articles for article (PubMed ID: 35254632)
1. Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic.
Rook ME; Southwell AL
BioDrugs; 2022 Mar; 36(2):105-119. PubMed ID: 35254632
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
3. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
4. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
5. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.
Kay C; Collins JA; Caron NS; Agostinho LA; Findlay-Black H; Casal L; Sumathipala D; Dissanayake VHW; Cornejo-Olivas M; Baine F; Krause A; Greenberg JL; Paiva CLA; Squitieri F; Hayden MR
Am J Hum Genet; 2019 Dec; 105(6):1112-1125. PubMed ID: 31708117
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
Dash D; Mestre TA
Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
[TBL] [Abstract][Full Text] [Related]
8. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
[TBL] [Abstract][Full Text] [Related]
9. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
[TBL] [Abstract][Full Text] [Related]
11. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R
Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.
Southwell AL; Skotte NH; Kordasiewicz HB; Østergaard ME; Watt AT; Carroll JB; Doty CN; Villanueva EB; Petoukhov E; Vaid K; Xie Y; Freier SM; Swayze EE; Seth PP; Bennett CF; Hayden MR
Mol Ther; 2014 Dec; 22(12):2093-2106. PubMed ID: 25101598
[TBL] [Abstract][Full Text] [Related]
14. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
Leavitt BR; Kordasiewicz HB; Schobel SA
JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
16. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
17. Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.
van Roon-Mom WMC; Roos RAC; de Bot ST
Nucleic Acid Ther; 2018 Apr; 28(2):59-62. PubMed ID: 29620999
[TBL] [Abstract][Full Text] [Related]
18. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the therapeutic development for Huntington disease.
Mestre TA
Parkinsonism Relat Disord; 2019 Feb; 59():125-130. PubMed ID: 30616867
[TBL] [Abstract][Full Text] [Related]
20. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
